Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have received a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $61.11.

A number of equities analysts have weighed in on HALO shares. Piper Sandler upped their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a report on Wednesday. Finally, JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $35,583,199.52. This represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 30,000 shares of company stock valued at $1,621,800 over the last quarter. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $49,000. GAMMA Investing LLC lifted its holdings in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the period. Toth Financial Advisory Corp bought a new position in Halozyme Therapeutics in the 3rd quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter valued at about $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $46.84 on Thursday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a market capitalization of $5.96 billion, a price-to-earnings ratio of 15.51, a PEG ratio of 0.43 and a beta of 1.23. The business has a 50-day moving average of $51.20 and a 200-day moving average of $54.14.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.